OBJECTIVES: To investigate knowledge and attitudes of different healthcare professionals in UK towards infliximab and insulin glargine biosimilars METHODS: UK medical consultants/registrars, nurses and pharmacists participated in anonymised, self-administered web-based survey distributed by professional associations. KEY FINDINGS: There were 234 respondents: medical consultants/registrars (150), nurses (58) and pharmacists (26). 76% of medical consultants/registrars, 84% of pharmacists and 53% of nurses understood what biosimilars were. Medical consultants/registrars and pharmacists had safety and efficacy concerns when switching patients compared to initiation. Nurses had similar levels of safety and efficacy concerns about initiation. CONCLUSION: Healthcare professionals were more comfortable with the initiation of biosimilars than switching current patients. Medical consultants/registrars and pharmacists were more informed than nurses.
OBJECTIVES: To investigate knowledge and attitudes of different healthcare professionals in UK towards infliximab and insulinglargine biosimilars METHODS: UK medical consultants/registrars, nurses and pharmacists participated in anonymised, self-administered web-based survey distributed by professional associations. KEY FINDINGS: There were 234 respondents: medical consultants/registrars (150), nurses (58) and pharmacists (26). 76% of medical consultants/registrars, 84% of pharmacists and 53% of nurses understood what biosimilars were. Medical consultants/registrars and pharmacists had safety and efficacy concerns when switching patients compared to initiation. Nurses had similar levels of safety and efficacy concerns about initiation. CONCLUSION: Healthcare professionals were more comfortable with the initiation of biosimilars than switching current patients. Medical consultants/registrars and pharmacists were more informed than nurses.
Authors: Louise C Druedahl; Sofia Kälvemark Sporrong; Marco van de Weert; Marie Louise De Bruin; Hans Hoogland; Timo Minssen; Anna Birna Almarsdóttir Journal: BioDrugs Date: 2021-04-08 Impact factor: 5.807
Authors: Evelien Moorkens; Arnold G Vulto; James Kent; Lindsay McClure; Richard Boldero; Thibault Vanhove; Steven Simoens; Isabelle Huys Journal: BioDrugs Date: 2021-01 Impact factor: 5.807